ICHNO-ECHNO 2022 - Abstract Book

S45

ICHNO-ECHNO 2022

PO-0080 P16 is a strong predictive factor in a clinical series of 514 head and neck cancers

S. saussez 1 , G. Descamps 2 , S. Furgiuele 3 , J.R. Lechien 4 , D. Dequanter 5 , F. Journe 2

1 Health institute, Laboratory of human anatomy and experimental oncology, Mons, Belgium; 2 University of Mons , Laboratory of human anatomy and experimental oncology, Mons , Belgium; 3 University of Mons, Laboratory of human anatomy and experimental oncology, Mons , Belgium; 4 Saint-Pierre Hospital, Department of Otolaryngology and Head and Neck Surgery, Brussels, Belgium; 5 Saint-Pierre Hospital , Department of Otolaryngology and Head and Neck Surgery, Brussels, Belgium Purpose or Objective Tobacco and alcohol are two main risk factors associated with head and neck squamous cell carcinomas (HNSCC). Moreover, human papillomavirus (HPV) are clearly involved in the carcinogenesis in some of these cancers; especially for oropharyngeal SCCs (OSCC). In young non-smoking and non-drinking patients (less than 10% of our patients), HPV + OSCCs are associated with a better prognosis. However, in Belgium, most patients present several risk factors. In this context, our study try to identify the most effective prognostic factors (among HPV, tobacco or alcohol) associated with a prognosis in a large clinical series of 514 HNSCCs. In a subgroup of OSCCs, the immune profiles (CD8, CD68, FoxP3) of p16+ versus p16- tumors are compared. Materials and Methods Among the 514 patients, we counted 228 oral cavity, 186 oropharyngeal and 100 laryngeal cancers. HPV status was determined through p16 immunohistochemistry (357 patients) or PCR (275 patients). Univariable, multivariable Cox analyses and Kaplan-Meier survival curves have been assessed for recurrence and survival. Results Based on p16 expression, analysis of overall survival (OS) showed a significantly better 5-year survival for patients with p16 + OSCCs (p=0.016). In the entire cohort of 514 patients with HNSCC, this analysis remains significant without distinction of location (p=0.005). However, univariate analysis evaluating the impact of p16 in each anatomical sites demonstrates that p16 positivity does not influence the survival of patients in the two others sites. Given the high prevalence of smokers and drinkers in our population, we assessed whether the prognosis was compromised by consumption patterns with regard to HPV status. Individually, tobacco and alcohol are significant prognostic indicators. However, our multivariate analysis revealed that only the p 16 status remains an independent prognostic factor for OS in OSCCs (p=0.047). Finally, a scoring system combining p16, tobacco, alcohol status was defined and was significantly associated with longer OS for non-smoker and non-drinker p16-positive OSCC patients. In a subgroup of OSCCS, the comparison of CD8, CD68 and FoxP3 into the intratumoral compartment was significantly greater for p16+ patients compared to p16- patients. However, no significant difference was observed when comparing the density of these immune cells to smoker-drinker status. Conclusion Our study confirmed that the p16 + OSCCs presented a better OS than p 16 -. P16 positivity was not associated with better prognosis for patients suffering from oral cavity and laryngeal SCCs. In OSCCs the better OS of p16+ tumors must be put into perspective with the better recruitment of T lymphocytes and macrophages. 1 NKI-AvL, Head and Neck Oncology and Surgery, Amsterdam, The Netherlands; 2 NKI-AvL, Head and Neck Oncoloy and Surgery, Amsterdam, The Netherlands Purpose or Objective The incidence of oropharyngeal squamous cell cancer (OPSCC) is rising due to HPV. The patient population is becoming younger and has an expected long-term survival. So far there is no significant difference found in survival and oncological outcomes among primary transoral surgery and radiotherapy. Prospective results on functional outcomes will emerge in the coming years. This leaves patients with the difficulty of choosing between treatments with similar oncological and survival outcomes, but with uncertainty in long-term functional outcomes. In this study, we want to identify the wants and needs of patients with OPSCC and use this information to develop a decision aid to help them make a treatment choice based on their preferences and needs. Materials and Methods The development of the decision aid was based on the International Patient Decision Aid Standards criteria. We followed the three phases in the development process. In phase 1, relevant literature was reviewed and compared to currently used counseling papers. We held semistructured in-depth interviews with twenty post-treatment patients and ten doctors from four head and neck centers in the Netherlands. Audio-recorded interviews were transcribed and analyzed. This was the base of the first version PDA. We then tested for comprehensibility and usability (phase 2) and the feasibility of the decision aid (phase 3). PO-0081 The development of a decision aid for operable oropharyngeal carcinoma in the Netherlands A. Heirman 1 , L. Van der Molen 1 , R. Dirven 1 , M. Van den Brekel 2